One of these could be the TF NF-κB, which is activated in response to EGFR-TKIs, drives survival of EGFR-dependent cancer cells, and whose genetic or pharmacologic inhibition can potentiate erlotinib-induced apoptosis in NSCLC models [289,290]. The gene discussed is EGFR; the disease is cancer.